Thermo Fisher Scientific and Seer Partner with Singapore's PRECISE-SG100K for Large-Scale Proteomics Study
核心洞察
Thermo Fisher Scientific (搜索) has partnered with PRECISE (搜索) to advance the PRECISE-SG100K study, one of Asia's most ambitious population-scale biobank initiatives involving approximately 100,000 Singapore residents.
The collaboration integrates multiple proteomics platforms including Olink Proximity Extension Assay, Orbitrap Astral mass spectrometry, and Seer's Proteograph Product Suite to create comprehensive multi-omic datasets.
Seer will provide deep, unbiased proteomics analysis on 10,000 samples from the cohort, combining with other technologies to enhance biomarker discovery and disease mechanism insights.
Thermo Fisher Scientific (搜索) Inc. has announced a strategic collaboration with Precision Health Research, Singapore (PRECISE (搜索)) to advance the PRECISE-SG100K study, marking a significant milestone in population-scale proteomics research. The partnership represents one of the region's most ambitious biobank initiatives, encompassing approximately 100,000 Singapore residents in a comprehensive multi-omic health study.
Integrated Proteomics Platform Strategy
Under the collaboration, Thermo Fisher will deploy an integrated proteomics strategy combining its Olink Proximity Extension Assay (PEA) platforms with the high-resolution Orbitrap Astral mass spectrometry system. These technologies will work alongside Seer's Proteograph Product Suite to deliver scalable, high-sensitivity protein measurement capabilities with deep, unbiased discovery proteomics.
"Proteomics at population scale represents one of the most powerful opportunities to understand disease in real time across the full continuum of health," said Marc N. Casper, chairman and chief executive officer of Thermo Fisher. "By combining our deep scientific expertise with industry-leading technologies, we are helping national health leaders translate complex biological data into insights that can fundamentally transform human health."
Seer's Deep Proteomics Contribution
Seer, Inc. has been selected to provide deep, unbiased proteomic analysis on 10,000 participants from PRECISE (搜索)-SG100K using its Proteograph Product Suite. This mass spectrometry-based proteomic workflow will deeply profile the plasma proteome (搜索), with data combined from Thermo Fisher Scientific (搜索)'s Olink Reveal and Thermo Scientific Orbitrap Astral mass spectrometers on the same sample set.
The Proteograph-Astral combination has demonstrated high-throughput, deep proteome coverage in large population studies, providing thousands of quantified proteins with peptide-level resolution. This approach strengthens mass spectrometry-based proteomics' ability to validate and extend signals detected by affinity-based platforms.
Multi-Ancestry Population Focus
PRECISE (搜索)-SG100K is designed to integrate genomic, proteomic, and other health data across a deeply phenotyped, multi-ancestry Asian population. The study has successfully completed its recruitment phase, engaging over 100,000 participants from Singapore's diverse, multi-ethnic population.
"A key goal of PRECISE (搜索)-SG100K is to create a deeply characterized, multi-ancestry resource that can reveal how genetics, environment and lifestyle shape disease risk and treatment response," said John Chambers, Chief Scientific Officer of PRECISE and Lead PI of PRECISE-SG100K study. "By adding deep, unbiased plasma proteomics enabled by Seer and Thermo Fisher, we can more directly link genomic variation to protein networks (搜索) and health outcomes, uncovering insights critical to ensuring precision medicine reflects the diversity of Asian populations."
Technological Integration and Validation
The PRECISE (搜索)-SG100K study integrates complementary proteomic technologies in parallel across a large, longitudinal population cohort, an approach that strengthens reproducibility, supports regulatory-grade evidence generation and enhances long-term translational value. This model reflects the growing recognition of proteomics not only as a discovery tool, but as foundational research infrastructure for precision medicine.
"National biobank initiatives require technologies that deliver both breadth and precision," said Karen Nelson, Ph.D., chief scientific officer at Thermo Fisher. "By integrating our differentiated technologies, we are enabling high-confidence biomarker identification and accelerating the path to translational application. This complementary strategy sets a new standard for multi-proteomics analysis and empowers researchers to see true disease biology with speed and at scale."
Global Biobank Experience
Thermo Fisher brings extensive experience supporting biobank infrastructure development and large-scale proteomics and genomics initiatives globally. The company is currently involved in some of the largest biobank efforts to date, including the UK Biobank Pharma Proteomics Project, FinnGen in Finland, and the Geisinger's MyCode Community Health Initiative in the United States. Collectively, these programs encompass analyses of more than one million samples.
Research Applications and Future Impact
Proteomics data generated with the Proteograph in population-scale cohorts like PRECISE (搜索)-SG100K are expected to support biomarker discovery across cardiometabolic, ophthalmic, neurologic and other complex diseases. The research will advance drug target biology, inform predictive models for disease risk and response in underrepresented populations, and provide an orthogonal framework for validating and prioritizing markers identified through affinity-based platforms.
"PRECISE (搜索)-SG100K is one of the most ambitious and carefully designed multi-omic health initiatives in the world," said Omid Farokhzad, Chair and CEO of Seer. "Seer's Proteograph was built with the vision that deep, unbiased proteomics becomes the mainstay for population-scale multi-omic studies, and PRECISE-SG100K is the evidence of the emergence of that shift."
The study will continue to monitor long-term health outcomes and identify environmental, lifestyle and genetic factors associated with diseases such as diabetes (搜索), hypertension (搜索), and cancer (搜索), positioning itself as one of the largest population health studies in Southeast Asia.